Biochemical and Hematologic Alterations Following Percutaneous Cryoablation of Liver Tumors: Experience in 48 Procedures
Authors:
- Stuart G. SilvermanSSStuart G. Silverman
- Kemal TuncaliKTKemal Tuncali
- Nancy A. ObuchowskiNONancy A. Obuchowski
- Eric VansonnenbergEVEric Vansonnenberg
- Sridhar ShankarSSSridhar Shankar
- 1 July 2008
- journal article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 248 (1) , 303-311
Abstract
To retrospectively determine the frequency and severity of various abnormal laboratory test values following percutaneous cryoablation of liver tumors and to estimate the correlation between laboratory test values and tumor and ablation volumes. This HIPAA-compliant study had institutional review board approval. Informed consent was waived. Biochemical and hematologic laboratory values from 48 procedures in 39 patients (18 men and 21 women; age range, 29-86 years) who underwent magnetic resonance (MR) imaging-guided percutaneous cryoablation of 65 liver tumors (62 metastases, three hepatocellular carcinomas) were retrospectively reviewed. Changes in laboratory values at baseline and 0-6 hours and 1-2 weeks after the procedure were analyzed with respect to tumor and ablative margin volumes by using generalized estimating equations. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were correlated with percent maximal decrease in platelet count. Mean ablation zone volume was 67.3 cm(3) +/- 41.2 (standard deviation) (range, 7.3-191.4 cm(3)). AST and ALT values increased after all procedures and peaked at 6 hours (median change in AST value, +835 U/L; median change in ALT value, +614.5 U/L). Platelet count decreased after 47 procedures (mean maximal decrease, 92.3 x 10(9)/L [38%]), reaching a nadir at 12-24 hours after 24 procedures (50%) and returning to normal in 31 (84%) of 37 procedures at 1-2 weeks. One procedure was complicated by disseminated intravascular coagulation that necessitated transfusion and arterial embolization. Myoglobin values increased after 21 (44%) of 48 procedures and peaked at 6 hours (trimmed-mean value, 183.4 mug/L). Ablative margin volumes were predictive of changes at 0-6 hours in AST (P = .02), ALT (P = .003), and myoglobin (P < .001) values. Percent maximal decrease in platelet count correlated with peak change in AST (r = 0.72) (P < .001). Following percutaneous cryoablation of liver tumors, alterations in liver enzymes, myoglobin, and platelet count are common, are usually self-limited, and correlate with ablative margin volume--except for changes in platelet count, which correlate with changes in AST and ALT.Keywords
This publication has 19 references indexed in Scilit:
- MR-guided percutaneous cryotherapy of malignant liver tumor under horizontal-magnetic open system: initial experienceJournal of Hepato-Biliary-Pancreatic Surgery, 2003
- Phase I study of percutaneous cryotherapy for colorectal liver metastasisBritish Journal of Surgery, 2002
- Biochemical, hematologic, and immunologic alterations following hepatic cryotherapySeminars in Surgical Oncology, 1998
- Cryoablation of unresectable malignant liver tumorsThe American Journal of Surgery, 1996
- Hepatic cryosurgery in treating colorectal metastasesCancer, 1995
- Hepatic Cryotherapy: Double-Freeze Cycles Achieve Greater Hepatocellular Injury in ManCryobiology, 1995
- Anaesthetic Experience with Cryotherapy for Treatment of Hepatic MalignancyAnaesthesia and Intensive Care, 1992
- A 5-Year Study of Cryosurgery in the Treatment of Liver TumorsArchives of Surgery, 1991
- Ultrasound-guided hepatic cryosurgery in the treatment of metastatic colon carcinoma. Preliminary resultsCancer, 1991
- Clinical evaluation of cryosurgery in the treatment of primary liver cancer Report of 60 CasesCancer, 1988